# CellFX® Nanosecond Pulsed Field Ablation (PFA) 360 Catheter Ablation System for Treatment of Atrial Fibrillation

> **NCT06696170** · NA · RECRUITING · sponsor: **Pulse Biosciences, Inc.** · enrollment: 60 (estimated)

## Conditions studied

- Atrial Fibrillation Paroxysmal
- Cardiac Ablation
- Cardiac Arrhythmia

## Interventions

- **DEVICE:** CellFX nano-pFA 360 Endocardial Ablation Catheter System

## Key facts

- **NCT ID:** NCT06696170
- **Lead sponsor:** Pulse Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-25
- **Primary completion:** 2026-06-25
- **Final completion:** 2026-07-25
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06696170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06696170, "CellFX® Nanosecond Pulsed Field Ablation (PFA) 360 Catheter Ablation System for Treatment of Atrial Fibrillation". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06696170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*